Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Open-label Tolvaptan Trial in Pediatric ARPKD
2023-508218-41-00Phase 3Authorised
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in autosomal recessive polycystic kidney disease (ARPKD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety assessments, Serum transaminase elevations and 1 more. Planned start May 2024; status: authorised.
02
Drugs
tolvaptan
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)
Beyond the preview
Go deeper on 2023-508218-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508218-41-00.